Aligning Management Group provided New Refined Industrial Concentrate on Institutions Beginning with Current Appointment of Board Member Zhenya Lindgardt as Interim President and CEO
Engages Major Technique Property to Evaluate Most effective Pathways Toward Targeting Enhanced Income Generation at Substantially Decreased Operating Charges
Nadia Altomare Anticipated to Move from Chief Industrial Officer to Consulting Function to Assistance Driving Efficiency and Effectiveness in Our Industrial Invest in Partnership with Our External and Internal Group
SALT LAKE CITY, May possibly 25, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on enhancing maternal and neonatal overall health by offering revolutionary pregnancy biomarker information and facts to physicians and sufferers, currently announced specific industrial modifications and plans to optimize its technique and industrial structure to very concentrate enterprise activities on accelerating test adoption and income at substantially decreased operating fees.
These plans incorporate modifications to greater align leadership with a new refined industrial concentrate on institutions and price-successfully accelerating test adoption and income in advance of upcoming information readouts. This method began with the current appointment of Board Member Zhenya Lindgardt, a seasoned enterprise operator for higher-development organizations, as interim President and CEO, announced on May possibly 15, 2023.
Sera Prognostics has also engaged a major technique home to rigorously evaluate the very best pathways toward enhanced income at substantially decreased price to a lot more broadly commercialize the company’s PreTRM® Test and pipeline of technologies. This evaluation is anticipated to be inclusive of effective marketplace concentrate and possible strategic partnerships. As portion of this method, Nadia Altomare is anticipated to move from Chief Industrial Officer to a consulting function to help driving efficiency and effectiveness in our industrial commit in partnership with our external and internal group.
The Organization has also produced choose headcount reductions at month finish in its industrial organization to greater map present industrial and marketing and advertising fees toward refined concentrate on these possibilities getting deemed as the most profitable in the close to-term from a test adoption and income generation point of view. Sera Prognostics is evaluating other techniques to additional optimize its enterprise whilst minimizing operating fees and guarding its robust balance sheet, which at present affords a robust foundation toward realization of the Company’s ambitions outlined currently coupled with targeting enhanced shareholder valuation.
“We are taking decisive and effectively-defined actions to optimize for marketplace achievement provided the macro atmosphere, whilst also taking into consideration the emerging function we seek to play in establishing our initially-of-its-sort PreTRM test as a normal of care in guarding mothers and babies,” mentioned Sera Prognostics interim CEO, Zhenya Lindgardt. “Although alter is at instances difficult, we anticipate our actions will prove thriving in supporting our aim to be The Pregnancy Organization whilst fostering substantial development, and we are thankful for our team’s function in developing a paradigm shift in pregnancy care to build greater healthcare outcomes for expectant mothers and their youngsters.”
About Sera Prognostics, Inc.
Sera Prognostics is a major overall health diagnostics organization committed to enhancing the lives of females and babies by way of precision pregnancy care. Sera’s mission is to deliver early, pivotal pregnancy information and facts to strengthen the overall health of mothers and newborns, resulting in reductions in the fees of healthcare delivery. Sera has a robust pipeline of revolutionary diagnostic tests focused on the early prediction of preterm birth danger and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a doctor the individualized danger of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in females with greater danger. Sera Prognostics is situated in Salt Lake City, Utah.
About Preterm Birth
Preterm birth is defined as any birth ahead of 37 weeks’ gestation and is the major trigger of illness and death in newborns. The 2022 March of Dimes Report Card shows that, for the final 4 consecutive years, a lot more than one particular in ten infants is born prematurely. Prematurity is linked with a substantially elevated danger of important extended-term healthcare complications, like studying disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can create substantial fees all through the lives of impacted youngsters. The annual overall health care fees to handle quick- and extended-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially accessible blood-primarily based biomarker test that gives an early, correct and individualized danger prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are very predictive of preterm birth. The PreTRM® Test permits physicians to recognize, throughout the weeks 18 by way of 20 of pregnancy, which females are at elevated danger for preterm birth and its complications, enabling a lot more informed, customized clinical choices primarily based on every single woman’s person danger. The PreTRM® Test is ordered by a healthcare qualified.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy Organization, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other nations.
Protected Harbor Statement
This press release includes “forward-searching statements” inside the which means of the Private Securities Litigation Reform Act of 1995, like statements relating to accelerating test adoption and income targeting enhanced income generation at substantially decreased operating fees driving efficiency and effectiveness in our industrial commit upcoming information readouts possible strategic partnerships additional optimizing the Company’s enterprise enhanced shareholder valuation establishing the Company’s initially-of-its-sort PreTRM test as a normal of care fostering substantial development and the company’s strategic directives below the caption “About Sera Prognostics, Inc.” These “forward-searching statements” are primarily based on management’s present expectations of future events and are topic to a quantity of dangers and uncertainties that could trigger actual outcomes to differ materially and adversely from these set forth in or implied by forward-searching statements. These dangers and uncertainties incorporate, but are not restricted to: net losses, money generation, and the possible need to have to raise a lot more capital revenues from the PreTRM Test representing substantially all Organization revenues to date the need to have for broad scientific and marketplace acceptance of the PreTRM Test a concentrated quantity of material consumers our capacity to introduce new merchandise possible competitors our proprietary biobank crucial suppliers the COVID-19 pandemic and its possible lingering influence on our operations, as effectively as the enterprise or operations of third parties with whom we conduct enterprise estimates of total addressable marketplace chance and forecasts of marketplace development possible third-celebration payer coverage and reimbursement new reimbursement methodologies applicable to the PreTRM Test, like new CPT codes and payment prices for these codes modifications in FDA regulation of laboratory-created tests the intellectual home rights guarding our tests and marketplace position and other things discussed below the heading “Threat Components” contained in our Final Prospectus on Type S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as effectively as any updates to these danger things filed from time to time in our Quarterly Reports on Type ten-Q, Annual Reports on Type ten-K, or Present Reports on Type eight-K. All information and facts in this press release is as of the date of the release, and the Organization undertakes no duty to update this information and facts unless necessary by law.
Supply Sera Prognostics, Inc.